Toxicogenomics in drug discovery and drug development: Potential applications and future challenges

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1659-1664

  Khor, Tin Oo ^a   Ibrahim, Sherif ^a   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Gene expression profiles; Microarray; Pharmacogenomics; Signal transduction; Toxicogenomics

Indexed keywords

2 METHOXYETHANOL; ACETONYLACETONE; ANTIHISTAMINIC AGENT; CURCUMIN; CYCLOPHOSPHAMIDE; METHAPYRILENE; PEROXISOME PROLIFERATOR; SALAZOSULFAPYRIDINE; SULFORAPHANE;

BIOASSAY; CELL CULTURE; COMPUTER MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TOXICOGENETICS; TOXICOGENOMICS;

ANIMALS; DATABASES, GENETIC; DRUG DESIGN; HUMANS; PHARMACOLOGY; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; TOXICOGENETICS;

EID: 33746922421     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9003-8     Document Type: Review

References (57)

1. H. van de Waterbeemd and E. Gifford. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2:192-204 (2003).
2. H. van de Waterbeemd and E. Gifford. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov.2:192-204 (2003).
3. S. Ekins, Y. Nikolsky, and T. Nikolskaya. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26:202-209 (2005).
4. A. M. Davis and R. J. Riley. Predictive ADMET studies, the challenges and the opportunities. Curr. Opin. Chem. Biol. 8:378-386 (2004).
5. E. F. Nuwaysir, M. Bittner, J. Trent, J. C. Barrett, and C. A. Afshari. Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog. 24:153-159 (1999).
6. M. J. Aardema and J. T. MacGregor. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 499:13-25 (2002).
7. M. R. Fielden and T. R. Zacharewski. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol. Sci. 60:6-10 (2001).
8. R. D. Irwin, G. A. Boorman, M. L. Cunningham, A. N. Heinloth, D. E. Malarkey, and R. S. Paules. Application of toxicogenomics to toxicology: basic concepts in the analysis of microarray data. Toxicol. Pathol. 32(Suppl 1):72-83 (2004).
9. G. Orphanides and I. Kimber. Toxicogenetics: applications and opportunities. Toxicol. Sci. 75:1-6 (2003).
10. T. W. Gant and S. D. Zhang. In pursuit of effective toxicogenomics. Mutat. Res. 575:4-16 (2005).
11. A. Luhe, L. Suter, S. Ruepp, T. Singer, T. Weiser, and S. Albertini. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat. Res. 575:102-115 (2005).
12. K. R. Hayes and C. A. Bradfield. Advances in toxicogenomics. Chem. Res. Toxicol. 18:403-414 (2005).
13. M. McMillian, A. Nie, J. B. Parker, A. Leone, M. Kemmerer, S. Bryant, J. Herlich, L. Yieh, A. Bittner, X. Liu, J. Wan, M. D. Johnson, and P. Lord. Drug-induced oxidative stress in rat liver from a toxicogenomics perspective. Toxicol. Appl. Pharmacol. 207:171-178 (2005).
14. S. K. Thukral, P. J. Nordone, R. Hu, L. Sullivan, E. Galambos, V. D. Fitzpatrick, L. Healy, M. B. Bass, M. E. Cosenza, and C. A. Afshari. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33:343-355 (2005).
15. G. Steiner, L. Suter, F. Boess, R. Gasser, C. Verade, S. Albertini, and S. Ruepp. Discriminating different classes of toxicants by transcript profiling. Environ. Health. Perspect. 112:1236-1248 (2004).
16. K. Boekelheide, J. Lee, E. B. Shipp, J. H. Richburg, and G. Li. Expression of Fas system-related genes in the testis during development and after toxicant exposure. Toxicol. Lett. 102-103:503-508 (1998).
17. J. Lee, J. H. Richburg, E. B. Shipp, M. L. Meistrich, and K. Boekelheide. The Fas system, a regulator of testicular germ cell apoptosis, is differentially up-regulated in Sertoli cell versus germ cell injury of the testis. Endocrinology 140:852-858 (1999).
18. T. Fukushima, T. Yamamoto, R. Kikkawa, Y. Hamada, M. Komiyama, C. Mori, and I. Horii. Effects of male reproductive toxicants on gene expression in rat testes. J. Toxicol. Sci. 30:195-206 (2005).
19. J. F. Waring, R. A. Jolly, R. Ciurlionis, P. Y. Lum, J. T. Praestgaard, D. C. Morfitt, B. Buratto, C. Roberts, E. Schadt, and R. G. Ulrich. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175:28-42 (2001).
20. F. de Longueville, D. Surry, G. Meneses-Lorente, V. Bertholet, V. Talbot, S. Evrard, N. Chandelier, A. Pike, P. Worboys, J. P. Rasson, B. Le Bourdelles, and J. Remacle. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem. Pharmacol. 64:137-149 (2002).
21. Y. Hong, U. R. Muller, and F. Lai. Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol. in Vitro 17:85-92 (2003).
22. F. Boess, M. Kamber, S. Romer, R. Gasser, D. Muller, S. Albertini, and L. Suter. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 73:386-402 (2003).
23. W. Pfaller, M. Balls, R. Clothier, S. Coecke, P. Dierickx, B. Ekwall, B. A. Hanley, T. Hartung, P. Prieto, M. P. Ryan, G. Schmuck, D. Sladowski, J. A. Vericat, A. Wendel, A. Wolf, and J. Zimmer. Novel advanced in vitro methods for long-term toxicity testing: the report and recommendations of ECVAM workshop 45. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 29:393-426 (2001).
24. G. Shen, C. Xu, R. Hu, M. R. Jain, S. Nair, W. Lin, C. S. Yang, J. Y. Chan, and A. N. Kong. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res. 22:1805-1820 (2005).
25. C. Chen and A. N. Kong. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic. Biol. Med. 36:1505-1516 (2004).
26. C. Xu, Y. Li, and A. N. Kong. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28:249-268 (2005).
27. G. Shen, C. Xu, R. Hu, M. R. Jain, A. Gopalkrishnan, S. Nair, M. T. Huang, J. Y. Chan, and A. N. Kong. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther 5:39-51 (2006).
28. R. Hu, C. Xu, G. Shen, M. R. Jain, T.O. Khor, A. Gopalkrishnan, W. Lin, B. Reddy, J. Y. Chan, and A.N. Kong. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett. (2006) Mar 2; [Epub ahead of print].
29. T. P. Dalton, M. Z. Dieter, R. S. Matlib, N. L. Childs, H. G. Shertzer, M. B. Genter, and D. W. Nebert. Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem. Biophys. Res. Commun. 267:184-189 (2000).
30. Y. Tsuneoka, T. P. Dalton, M. L. Miller, C. D. Clay, H. G. Shertzer, G. Talaska, M. Medvedovic, and D. W. Nebert. 4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J. Natl. Cancer Inst. 95:1227-1237 (2003).
31. S. Uno, T. P. Dalton, H. G. Shertzer, M. B. Genter, D. Warshawsky, G. Talaska, and D. W. Nebert. Benzo[a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem. Biophys. Res. Commun. 289:1049-1056 (2001).
32. G. Talaska, D. Ginsburg, K. Ladow, A. Puga, T. Dalton, and D. Warshawsky. Impact of Cyp1a2 or Ahr gene knockout in mice: implications for biomonitoring studies. Toxicol. Lett. (2005).
33. S. Hasmall, G. Orphanides, N. James, W. Pennie, K. Hedley, A. Soames, I. Kimber, and R. Roberts. Downregulation of lactoferrin by PPARalpha ligands: role in perturbation of hepatocyte proliferation and apoptosis. Toxicol. Sci. 68:304-313 (2002).
34. Q. Y. Zhang, J. Gu, T. Su, H. Cui, X. Zhang, J. D'Agostino, X. Zhuo, W. Yang, P.J. Swiatek, and X. Ding. Generation and characterization of a transgenic mouse model with hepatic expression of human C-P2A6. Biochem. Biophys. Res. Commun. 338:318-324 (2005).
35. H. Olson, G. Betton, J. Stritar, and D. Robinson. The predictivity of the toxicity of pharmaceuticals in humans from animal data - an interim assessment. Toxicol. Lett. 102-103:535-538 (1998).
36. H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, and A. Heller. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32:56-67 (2000).
37. M. Habs, P. Shubik, and G. Eisenbrand. Carcinogenicity of methapyrilene hydrochloride, mepyramine hydrochloride, thenyldiamine hydrochloride, and pyribenzamine hydrochloride in Sprague-Dawley rats. J. Cancer Res. Clin. Oncol. 111:71-74 (1986).
38. W. Lijinsky, M. D. Reuber, and B. N. Blackwell. Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride. Science 209:817-819 (1980).
39. W. Lijinsky. Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem. Toxicol. 22:27-30 (1984).
40. L. M. Brennan and D. A. Creasia. The effects of methapyrilene hydrochloride on hepatocarcinogenicity and pentobarbital-induced sleeping time in rats and mice. Toxicol. Appl. Pharmacol. 66:252-258 (1982).
41. W. Lijinsky, G. Knutsen, and M. D. Reuber. Failure of methapyrilene to induce tumors in hamsters or guinea pigs. J. Toxicol. Environ. Health 12:653-657 (1983).
42. J. C. Mirsalis. Genotoxicity, toxicity, and carcinogenicity of the antihistamine methapyrilene. Mutat. Res. 185:309-317 (1987).
43. P. R. Holden and J. D. Tugwood. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22:1-8 (1999).
44. R. A. Roberts. Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences. Arch. Toxicol. 73:413-418 (1999).
45. J. W. Lawrence, G. K. Wollenberg, J. D. Frank, and J. G. DeLuca. Dexamethasone selectively inhibits WY14,643-induced cell proliferation and not peroxisome proliferation in mice. Toxicol. Appl. Pharmacol. 170:113-123 (2001).
46. D. J. Hoivik, C. W. Qualls Jr., R. C. Mirabile, N. F. Cariello, C. L. Kimbrough, H. M. Colton, S. P. Anderson, M. J. Santostefano, R. J. Morgan, R. R. Dahl, A. R. Brown, Z. Zhao, P. N. Mudd Jr., W. B. Oliver Jr., H. R. Brown, and R. T. Miller. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 25:1757-1769 (2004).
47. J. F. Waring and M. G. Anderson. Idiosyricratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr. Opin. Drug Discov. Devel. 8:59-65 (2005).
48. J. Robert, V. L. Morvan, D. Smith, P. Pourquier, and J. Bonnet. Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol. 54:171-196 (2005).
49. W. P. Petros and W. E. Evans. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol. Sci. 25:457-464 (2004).
50. G. C. Tseng, M. K. Oh, L. Rohlin, J. C. Liao, and W. H. Wong. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res. 29:2549-2557 (2001).
51. A. H. Salter and K. C. Nilsson. Informatics and multivariate analysis of toxicogenomics data. Curr. Opin. Drug Discov. Devel. 6:117-122 (2003).
52. A. Brazma, P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J. Aach, W. Ansorge, C. A. Ball, H. C. Causton, T. Gaasterland, P. Glenisson, F. C. Holstege, I. F. Kim, V. Markowitz, J. C. Matese, H. Parkinson, A. Robinson, U. Sarkans, S. Schulze-Kremer, J. Stewart, R. Taylor, J. Vilo, and M. Vingron. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29:365-371 (2001).
53. J. D. Pollock. Gene expression profiling: methodological challenges, results, and prospects for addiction research. Chem. Phys. Lipids 121:241-256 (2002).
54. T. B. Knudsen and G. P. Daston. MIAME guidelines. Reprod. Toxicol. 19:263 (2005).
55. M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863-14868 (1998).
56. A. Liu, Y. Zhang, E. Gehan, and R. Clarke. Block principal component analysis with application to gene microarray data classification. Stat. Med. 21:3465-3474 (2002).
57. C. Ambroise and G. J. McLachlan. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc. Natl. Acad. Sci. USA 99:6562-6566 (2002).